Document Detail


Prevention of deep-vein thrombosis following total hip replacement surgery with enoxaparin versus unfractionated heparin: a pharmacoeconomic evaluation.
MedLine Citation:
PMID:  8173149     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
OBJECTIVE: To compare the use of healthcare services in patients receiving enoxaparin, a low molecular weight heparin versus those receiving unfractionated heparin as prophylaxis against deep-vein thrombosis (DVT) following total hip replacement surgery. DESIGN: Economic evaluation undertaken in conjunction with a randomized, open-label, parallel group, Phase III clinical trial. SETTING: 32 US acute-care hospitals. PATIENTS: 607 patients undergoing elective total hip replacement. INTERVENTIONS: Enoxaparin 30 mg q12h, enoxaparin 40 mg qd, or unfractionated heparin 5000 units q8h started within 24 hours following surgery and continued for 7 days. MAIN OUTCOME MEASURES: (1) Use of selected tests and treatments for DVT; (2) use of selected tests and treatments related to postoperative bleeding; (3) length of stay in hospital; and (4) readmissions to hospital within 14 days. RESULTS: Although the use of selected tests and treatments related to DVT or postoperative bleeding did not differ significantly between the three treatment groups, mean length of stay in the hospital (following the start of study therapy) was shorter among patients receiving enoxaparin 30 mg (9.5 days; p = 0.01) or 40 mg (9.9 days; p < 0.05) than those receiving unfractionated heparin (11.3 days). There was also a trend toward fewer hospital readmissions in both of the enoxaparin groups. CONCLUSIONS: Compared with unfractionated heparin, use of enoxaparin following total hip replacement may decrease the risk of DVT and length of hospital stay.
Authors:
J Menzin; R Richner; D Huse; G A Colditz; G Oster
Related Documents :
17764219 - The uses of heparin to treat burn injury.
15660059 - The effect of intraoperative heparin administered during total hip arthroplasty on the ...
55029 - Clinical and haemostatic parameters related to thromboembolism and low-dose heparin pro...
16430639 - Venogenic erectile dysfunction in klippel-trenaunay syndrome.
1406229 - Further investigation of secondary venous obstruction.
1316259 - Prevention of deep vein thrombosis in orthopaedic surgery. comparison of two different ...
10508809 - Characteristics of polyclonal endemicity of pseudomonas aeruginosa colonization in inte...
9743169 - Long-term results of fiberoptic bronchoscopic balloon dilation in the management of ben...
4030819 - Total condylar knee replacement. a study of factors influencing range of motion as late...
Publication Detail:
Type:  Clinical Trial; Clinical Trial, Phase III; Comparative Study; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't    
Journal Detail:
Title:  The Annals of pharmacotherapy     Volume:  28     ISSN:  1060-0280     ISO Abbreviation:  Ann Pharmacother     Publication Date:  1994 Feb 
Date Detail:
Created Date:  1994-06-09     Completed Date:  1994-06-09     Revised Date:  2006-11-15    
Medline Journal Info:
Nlm Unique ID:  9203131     Medline TA:  Ann Pharmacother     Country:  UNITED STATES    
Other Details:
Languages:  eng     Pagination:  271-5     Citation Subset:  IM    
Affiliation:
Department of Medicine, Brigham and Women's Hospital, Boston, MA.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Adult
Aged
Aged, 80 and over
Economics, Pharmaceutical
Enoxaparin / economics,  therapeutic use*
Heparin / economics,  therapeutic use*
Hip Prosthesis*
Humans
Length of Stay
Middle Aged
Postoperative Complications / prevention & control*
Thrombophlebitis / prevention & control*
Chemical
Reg. No./Substance:
0/Enoxaparin; 9005-49-6/Heparin

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Use of antifungal therapy in hospitalized patients. II. Results after the marketing of fluconazole.
Next Document:  Pharmacists as members of the healthcare team in Israel: sectoral differences.